This Company Could Have A Cure For Highly Resistant Tumors
Moleculin Biotech, Inc. (Nasdaq: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors.
The company announced that its ongoing sponsored research at The University of Texas MD Anderson Cancer Center has now demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models.
Walter Klemp, Moleculin’s Chairman and CEO, commented: “We know that Annamycin was previously shown to be significantly more potent than doxorubicin in both Lewis lung carcinoma in vivo and small cell lung cancer in vitro models.”
He continued: “Now we are seeing significant activity against triple negative breast cancer that has metastasized to the lungs. This particular animal model used in our testing is considered to represent a very aggressive form of cancer.
Don't Rely on Dividends Alone…
Many of the market’s largest dividend payers have taken heavy losses over the past few years... and it could get even more dire. A new book, titled “Income for Life” details more than 65 little-known income streams that ANYONE can collect.
We believe our success in increasing the survival rate in mice with this tumor model in combination with the previously observed high uptake of Annamycin by the lungs is a promising indication that supports additional clinical research in lung and metastatic lung cancers.”
According to PR Newswire,
The company also announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. The study will be conducted at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta.
Kemp also commented on this agreement: “Given the exciting data Emory University researchers presented at the recent Society for Neuro Oncology conference, we have been working closely with them to begin a trial in pediatric brain tumors.”
He added: “WP1066 was shown to have a significant anti-tumor effect on medulloblastoma cell lines, so there is a lot of encouragement regarding the opportunity to provide new hope for treating this rare condition.
This will also give us yet another opportunity to develop human proof of concept data, bringing our total number of clinical trials to five. This clinical trial is expected to begin recruitment in the second half of this year.”
The second half of 2019 could provide gains to patient investors.
MBRX should be considered a buy if recent momentum continues.
Look for an entry at $1.69 with a price target of at least $2.64 based on the pattern in the chart